GlassScriptPhysician profile
John K Waas
NPI 1093789489
$2,473.77
in general payments reported to CMS, 2019-2025
22 companies · $519 in 2025
The $519 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $261 · 2021: $340 · 2022: $548 · 2023: $182 · 2024: $144 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.31 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $349.07 | 2019-2025 | Welireg, Keytruda |
| Astrazeneca Pharmaceuticals LP | $288.14 | 2019-2022 | |
| Blueprint Medicines Corporation | $215.48 | 2022-2025 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $198.00 | 2020-2021 | |
| Seagen INC. | $164.71 | 2020-2021 | |
| Servier Pharmaceuticals LLC | $133.27 | 2025 | |
| Exelixis INC. | $132.53 | 2022-2023 | Cabometyx |
| Lilly USA, LLC | $124.74 | 2023 | Verzenio |
| Eisai INC. | $122.01 | 2022 | |
| Celgene Corporation | $116.57 | 2020-2021 | |
| Adc Therapeutics America, INC. | $114.47 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.44 | 2019-2021 | |
| Janssen Biotech, INC. | $65.55 | 2019-2024 | Erleada |
| Astellas Pharma US INC | $63.52 | 2019 | |
| Amgen INC. | $62.53 | 2025 | Imdelltra (Amg757) |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $45.97 | 2025 | Brukinsa |
| Genentech USA, INC. | $43.92 | 2019 | |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Gilead Sciences, INC. | $29.24 | 2021-2025 | Trodelvy |
| Clovis Oncology, INC. | $24.51 | 2019 | |
| Abbvie INC. | $22.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Waas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.